CTOs on the Move

Eiger BioPharmaceuticals

www.eigerbio.com

 
Eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. Eiger`s pipeline includes preclinical NCEs from discovery as well repurposed clinical Rx agents shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.eigerbio.com
  • 2155 Park Boulevard
    Palo Alto, CA USA 94306
  • Phone: 877.899.2051

Executives

Name Title Contact Details

Funding

Eiger BioPharmaceuticals raised $25M on 01/04/2017
Eiger BioPharmaceuticals raised $75M on 06/07/2022

Similar Companies

AmCyte

AmCyte Inc. is a Santa Monica, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Exothera

Exothera is a CDMO delivering customized process development and GMP production services for viral vectors in Belgium

Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals (NASDAQ: SBPH) is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. Spring Bank is developing its most advanced SMNH product candidate, inarigivir soproxil (formerly referred to as SB 9200), for the treatment of viral diseases, including hepatitis B virus (HBV), and other SMNH product candidates, including SB 11285, the company`s lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of Interferon Genes, or STING, pathway.

Arbutus Biopharma

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. Our current focus areas include Hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses. To address HBV, we are developing a RNAi therapeutic, an oral PD-L1 inhibitor, and an oral RNA destabilizer to potentially identify a combination regimen with the aim of providing a functional cure for patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. We believe our lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening. It is currently being evaluated in multiple phase 2 clinical trials. We also have an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronavirus (including SARS-CoV-2). In addition, we are exploring oncology applications for our internal PD-L1 portfolio.

Vybion

Vybion is a Ithaca, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.